Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804980 · ClinicalTrials.gov registry record · Phase 4
Desifor-expand (mhif)
A Phase 4 study of Statin Adverse Reaction and Statin Therapy, sponsored by Minneapolis Heart Institute Foundation.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06804980 is a Phase 4 study of Statin Adverse Reaction and Statin Therapy that is actively recruiting participants, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06804980, a Phase 4 study of Statin Adverse Reaction and Statin Therapy, is actively recruiting participants, sponsored by Minneapolis Heart Institute Foundation.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rosuvastatin (Crestor)
Study Locations (1)
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06804980
The ClinicalTrials.gov registry entry for NCT06804980 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Heart Institute Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Statin Adverse Reaction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06804980 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06804980 about?
NCT06804980 is a clinical study titled "Desifor-expand (mhif)". The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
What is the current status of trial NCT06804980?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06804980 study?
This clinical trial studies the following conditions: Statin Adverse Reaction, Statin Therapy, Statin.
What interventions are being tested in trial NCT06804980?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin (Crestor) (DRUG).
Who is sponsoring clinical trial NCT06804980?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804980 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Statin Adverse Reaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.